Chordoma: Difference between revisions
Jump to navigation
Jump to search
imported>Daniel Mietchen |
imported>Daniel Mietchen |
||
| Line 16: | Line 16: | ||
Chordomas are most frequently identified on the basis of [[MRI|MRI scans]]. They can also, with lower probability, be identified on [[CT scan]]s, particularly if the tumour has grown considerably. [[Histology|Histologically]], chordomas can be identified using a variety of [[immunohistochemical]] markers. | Chordomas are most frequently identified on the basis of [[MRI|MRI scans]]. They can also, with lower probability, be identified on [[CT scan]]s, particularly if the tumour has grown considerably. [[Histology|Histologically]], chordomas can be identified using a variety of [[immunohistochemical]] markers. | ||
{{Image|Chordoma immunohistochemistry.png|right|250px|Different [[immunohistochemical marker]]s of chordoma. A: [[Ethyl eosin]] staining of a chordoma composed of nests and cords of tumour cells; B: Ethyl eosin staining of [[physaliphorous cell]]s containing multiple clear [[cytoplasm]]ic [[vacuole]]s; C: [[immunohistochemistry]] showing staining for [[S-100 protein]]; D: immunohistochemistry showing staining for [[cytokeratin]]; E: immunohistochemistry showing staining for [[Epithelial membrane antigen|EMA]]; F: immunohistochemistry showing staining for [[Vimentin]]. Scale: Panel A is 6.4 mm wide, all others 1.6 mm.}} | {{Image|Chordoma immunohistochemistry.png|right|250px|Different [[immunohistochemical marker]]s of chordoma. A: [[Ethyl eosin]] staining of a chordoma composed of nests and cords of tumour cells; B: Ethyl eosin staining of [[physaliphorous cell]]s containing multiple clear [[cytoplasm]]ic [[vacuole]]s; C: [[immunohistochemistry]] showing staining for [[S-100 protein]]; D: immunohistochemistry showing staining for [[cytokeratin]]; E: immunohistochemistry showing staining for [[Epithelial membrane antigen|EMA]]; F: immunohistochemistry showing staining for [[Vimentin]]. Scale: Panel A is 6.4 mm wide, all others 1.6 mm.}} | ||
==Genetics== | |||
At least one [[susceptibility gene]] has been identified<ref name=Yang2009>{{CZ:Ref:Yang 2009 T (brachyury) gene duplication confers major susceptibility to familial chordoma}}</ref> | |||
==Therapy== | ==Therapy== | ||
Although variants of [[chemotherapy]] can achieve [[partial response]] or [[static disease]] in some cases<ref>[http://www.chordomafoundation.org/treatment/treatments.aspx Treatments options] — a list compiled by the [[Chordoma Foundation]] on the basis of the peer-reviewed literature on the subject</ref>, no therapy is in sight. This leaves [[surgery]] as the main option of treatment<ref>{{CZ:Ref:Boriani 2006 Chordoma of the mobile spine: fifty years of experience}}</ref>, with prospects of success varying according to location. | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 06:53, 17 May 2010
(CC) Image: Hassan et al., 2008
MRI scan of a patient with a very pronounced chordoma (yellow circle) in the clival region (green circle).
MRI scan of a patient with a very pronounced chordoma (yellow circle) in the clival region (green circle).
A chordoma (also known as choroid meningioma, chordocarcinoma, chordoepithelioma, or notochordoma) is a malignant tumor arising from the embryonic remains of the notochord.[1]
Etymology
The term derives — in analogy of carcinoma — from the Latin word chorda for string and the Greek suffix -oma designating a swelling.
Etiology
Chordomas are the result of abnormal tissue growth in remnants of the notochord. As such, they can occur anywhere in the bony tissue surrounding the spinal cord, with cranial, spinal and sacral tumours each representing about one third of the cases. The most common cranial location is in the clival region of the skull near the brainstem and the most common sacral lesion is in the body of the sacrum.[2]
Demographics
The prevalence is about 1 in a million in the United States, and affected patients have an average life expectancy of five to ten years after diagnosis, with differences according to age of onset, gender and ethnicity.[3]
Diagnostics
Chordomas are most frequently identified on the basis of MRI scans. They can also, with lower probability, be identified on CT scans, particularly if the tumour has grown considerably. Histologically, chordomas can be identified using a variety of immunohistochemical markers.
(CC) Photo: Larizza et al., 2005
Different immunohistochemical markers of chordoma. A: Ethyl eosin staining of a chordoma composed of nests and cords of tumour cells; B: Ethyl eosin staining of physaliphorous cells containing multiple clear cytoplasmic vacuoles; C: immunohistochemistry showing staining for S-100 protein; D: immunohistochemistry showing staining for cytokeratin; E: immunohistochemistry showing staining for EMA; F: immunohistochemistry showing staining for Vimentin. Scale: Panel A is 6.4 mm wide, all others 1.6 mm.
Different immunohistochemical markers of chordoma. A: Ethyl eosin staining of a chordoma composed of nests and cords of tumour cells; B: Ethyl eosin staining of physaliphorous cells containing multiple clear cytoplasmic vacuoles; C: immunohistochemistry showing staining for S-100 protein; D: immunohistochemistry showing staining for cytokeratin; E: immunohistochemistry showing staining for EMA; F: immunohistochemistry showing staining for Vimentin. Scale: Panel A is 6.4 mm wide, all others 1.6 mm.
Genetics
At least one susceptibility gene has been identified[4]
Therapy
Although variants of chemotherapy can achieve partial response or static disease in some cases[5], no therapy is in sight. This leaves surgery as the main option of treatment[6], with prospects of success varying according to location.
References
- ↑ Anonymous (2024), Chordoma (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Primary Malignant Bone Tumors: Tumors of Bones and Joints: Merck Manual Professional. Retrieved on 2010-05-14.
- ↑ McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM (2001). "Chordoma: incidence and survival patterns in the United States, 1973-1995". Cancer Causes Control 12 (1): 1-11. DOI:10.1023/A:1008947301735. PMID 11227920. Research Blogging. [e]
- Reports on a long-term study involving 400 patients with microscopically confirmed chordoma, revealing an overall prevalence of about 1 per million in the United States and a median survival time of about 6 years after diagnosis. It also shows that cranial, spinal and sacral locations each represent about one third of the total number of cases, and that males are affected about twice as often as females.
- ↑ Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S et al. (2009). "T (brachyury) gene duplication confers major susceptibility to familial chordoma". Nat Genet 41 (11): 1176-8. DOI:10.1038/ng.454. PMID 19801981. Research Blogging. [e]
- Based on comparative genomic hybridization data from four affected families, variations in the 6q27 region of the human chromosome 6 were found to be correlated with chordoma, thus suggesting the T gene as a potential susceptibility gene for the disease.
- ↑ Treatments options — a list compiled by the Chordoma Foundation on the basis of the peer-reviewed literature on the subject
- ↑ Boriani S, Bandiera S, Biagini R, Bacchini P, Boriani L, Cappuccio M et al. (2006). "Chordoma of the mobile spine: fifty years of experience". Spine (Phila Pa 1976) 31 (4): 493-503. DOI:10.1097/01.brs.0000200038.30869.27. PMID 16481964. Research Blogging. [e]
- Describes a set of 52 cases of chordoma along the mobile part of the spine (i.e. from the first thoracic to the fifth lumbar vertebra), discusses diagnostics, therapy and outcome and concludes that complete resection of the tumour is the only promising treatment.